Edition:
United States

Novartis AG (NVS)

NVS on New York Consolidated

86.16USD
22 Sep 2017
Change (% chg)

$1.22 (+1.44%)
Prev Close
$84.94
Open
$86.25
Day's High
$86.34
Day's Low
$85.85
Volume
2,726,428
Avg. Vol
1,890,034
52-wk High
$86.90
52-wk Low
$66.93

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 0.75
Market Cap(Mil.): $224,990.41
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.72
Yield (%): 3.15

Financials

  Industry Sector
P/E (TTM): -- 31.67 16.08
EPS (TTM): -- -- --
ROI: -- 15.12 14.60
ROE: -- 16.35 14.03

Three tips for smart dividend ETF plays

NEW YORKPop quiz: What percentage of long-term stock market returns are thanks to the humble dividend? Five? 10? 20?

Sep 21 2017

RPT-YOUR MONEY-Three tips for smart dividend ETF plays

NEW YORK, Sept 21Pop quiz: What percentage of long-term stock market returns are thanks to the humble dividend? Five? 10? 20?

Sep 21 2017

YOUR MONEY-Three tips for smart dividend ETF plays

NEW YORK, Sept 21Pop quiz: What percentage of long-term stock market returns are thanks to the humble dividend? Five? 10? 20?

Sep 21 2017

Novartis's Rydapt wins EU approval for AML, other diseases

ZURICH Swiss drugmaker Novartis on Wednesday won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals the medicine secured in April.

Sep 20 2017

Novartis's Rydapt wins EU approval for AML, other diseases

ZURICH Swiss drugmaker Novartis on Wednesday won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals the medicine secured in April.

Sep 20 2017

UPDATE 1-Novartis's Rydapt wins EU approval for AML, other diseases

ZURICH, Sept 20 Swiss drugmaker Novartis on Wednesday won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals the medicine secured in April.

Sep 20 2017

Novartis's Rydapt wins EU approval for AML, other diseases

ZURICH, Sept 20 Swiss drugmaker Novartis on Wednesday said it had won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals it secured in April.

Sep 20 2017

Fitch Revises Novartis' Outlook to Negative; 'AA' Affirmed

(The following statement was released by the rating agency) LONDON, September 18 (Fitch) Fitch Ratings has revised Switzerland-based pharmaceutical company Novartis AG's Outlook to Negative from Stable. Its Long-Term Issuer Default Rating (IDR) and senior secured rating have been affirmed at 'AA' and Short-Term IDR at 'F1+'. Fitch has also affirmed at 'AA' the unsecured rating of the notes issued by Novartis Finance S.A., Novartis Capital Corp., and Novartis Securities Investments Ltd., all gua

Sep 18 2017

Biosimilar cancer drug threat closing in for Roche

LONDON The long-heralded threat of cut-price competition to its top-selling biological cancer medicines is finally becoming a reality for Roche, the world's biggest maker of oncology treatments.

Sep 18 2017

Biosimilar cancer drug threat closing in for Roche

LONDON, Sept 18 The long-heralded threat of cut-price competition to its top-selling biological cancer medicines is finally becoming a reality for Roche, the world's biggest maker of oncology treatments.

Sep 18 2017

Competitors

Earnings vs. Estimates